Screener
Eli Lilly LLY Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $22.97B+47.7% | $19.8B+55.5% | $19.29B+42.6% | $17.6B+53.9% | $15.56B+37.6% | ||
| $3.27B+33.5% | $3.58B+60.8% | $3.37B+40.3% | $3.01B+38.6% | $2.45B+12.8% | ||
| $19.71B+50.3% | $16.22B+54.4% | $15.92B+43.0% | $14.59B+57.4% | $13.11B+43.6% | ||
| 85.8%+1.5pp | 81.9%-0.6pp | 82.5%+0.3pp | 82.9%+1.9pp | 84.3%+3.5pp | ||
| $3.82B+14.5% | $3.51B+28.4% | $3.8B+25.8% | $3.47B+26.8% | $3.34B+23.0% | ||
| $3.43B+24.6% | $2.93B+18.9% | $3.13B+29.1% | $2.74B+30.5% | $2.75B+30.0% | ||
| $269M+399% | -$65M+72.8% | -$108.3M+2.0% | -$133.1M-315% | -$90M+54.5% | ||
| $9.25B+36.4% | $8.85B+156% | $8.27B+64.1% | $7.23B+355% | $6.78B+92.7% | ||
| $2.15B+92.8% | $1.45B+109% | $1.63B+159% | $1.65B+167% | $1.12B+103% | ||
| $7.1B+25.3% | $7.4B+168% | $6.64B+50.5% | $5.58B+475% | $5.66B+90.8% | ||
| 30.9%-5.5pp | 37.4%+15.7pp | 34.4%+1.8pp | 31.7%+23.2pp | 36.4%+10.1pp | ||
| $7.94+26.2% | $8.26+170% | $7.39+51.4% | $6.21+480% | $6.29+91.8% | ||
| $9.78B+34.8% | $9.36B+139% | $8.85B+60.3% | $7.7B+275% | $7.26B+84.5% | ||
| 42.6%-4.1pp | 47.3%+16.5pp | 45.9%+5.1pp | 43.8%+25.8pp | 46.6%+11.8pp | ||
| $9.25B+36.4% | $8.85B+156% | $8.27B+64.1% | $7.23B+355% | $6.78B+92.7% |
FAQ
- What is Eli Lilly's revenue?
- Eli Lilly (LLY) generated $79.7B in revenue over the trailing twelve months, up 49.6% year over year.
- Is Eli Lilly profitable?
- Eli Lilly reported $26.7B in net income over the trailing twelve months, a 33.5% net margin.
- What is Eli Lilly's earnings per share?
- Eli Lilly's diluted EPS over the trailing twelve months is $29.80.
- Where does Eli Lilly's income statement data come from?
- Every line is extracted from Eli Lilly's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
